| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 173 | 2025 | 841 | 13.330 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 68 | 2025 | 176 | 9.300 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 76 | 2025 | 423 | 8.650 |
Why?
|
| Antineoplastic Agents | 111 | 2024 | 2422 | 5.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 140 | 2025 | 2642 | 5.670 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 66 | 2023 | 944 | 5.260 |
Why?
|
| Leukemia, Myeloid | 71 | 2016 | 252 | 4.840 |
Why?
|
| Pyrimidines | 50 | 2021 | 386 | 4.410 |
Why?
|
| Protein Kinase Inhibitors | 40 | 2025 | 611 | 4.290 |
Why?
|
| Neoplasms, Second Primary | 27 | 2022 | 247 | 3.800 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 32 | 2024 | 151 | 3.700 |
Why?
|
| Piperazines | 42 | 2015 | 296 | 3.480 |
Why?
|
| Cytarabine | 77 | 2023 | 225 | 3.410 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 36 | 2023 | 132 | 3.340 |
Why?
|
| Fusion Proteins, bcr-abl | 36 | 2024 | 110 | 3.260 |
Why?
|
| Myelodysplastic Syndromes | 53 | 2020 | 379 | 3.160 |
Why?
|
| Remission Induction | 98 | 2025 | 769 | 3.140 |
Why?
|
| Imatinib Mesylate | 51 | 2024 | 127 | 2.870 |
Why?
|
| Chromosome Aberrations | 55 | 2022 | 393 | 2.680 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 18 | 2023 | 24 | 2.470 |
Why?
|
| Leukemia, Promyelocytic, Acute | 16 | 2022 | 48 | 2.440 |
Why?
|
| Mutation | 67 | 2025 | 4374 | 2.410 |
Why?
|
| Humans | 569 | 2025 | 96127 | 2.290 |
Why?
|
| Adult | 313 | 2025 | 28718 | 2.270 |
Why?
|
| Middle Aged | 320 | 2025 | 28363 | 2.210 |
Why?
|
| Aged | 278 | 2025 | 20964 | 2.180 |
Why?
|
| Treatment Outcome | 156 | 2025 | 9173 | 1.960 |
Why?
|
| Disease-Free Survival | 74 | 2023 | 1195 | 1.890 |
Why?
|
| Prognosis | 116 | 2025 | 4033 | 1.790 |
Why?
|
| Staurosporine | 7 | 2022 | 34 | 1.770 |
Why?
|
| Vidarabine | 27 | 2015 | 146 | 1.760 |
Why?
|
| Male | 329 | 2025 | 45870 | 1.710 |
Why?
|
| Female | 325 | 2025 | 50063 | 1.710 |
Why?
|
| Survival Analysis | 72 | 2020 | 1546 | 1.660 |
Why?
|
| Leukemia | 35 | 2022 | 328 | 1.660 |
Why?
|
| MicroRNAs | 26 | 2016 | 592 | 1.640 |
Why?
|
| Daunorubicin | 34 | 2023 | 78 | 1.580 |
Why?
|
| Benzamides | 42 | 2015 | 248 | 1.580 |
Why?
|
| Aged, 80 and over | 116 | 2025 | 7232 | 1.570 |
Why?
|
| Transplantation Conditioning | 27 | 2021 | 383 | 1.560 |
Why?
|
| Survival Rate | 63 | 2025 | 1986 | 1.550 |
Why?
|
| Adolescent | 133 | 2025 | 9896 | 1.470 |
Why?
|
| Gene Expression Regulation, Leukemic | 25 | 2018 | 99 | 1.430 |
Why?
|
| Transplantation, Homologous | 43 | 2021 | 1023 | 1.400 |
Why?
|
| Dasatinib | 14 | 2021 | 39 | 1.390 |
Why?
|
| Azacitidine | 13 | 2025 | 150 | 1.340 |
Why?
|
| Consolidation Chemotherapy | 6 | 2018 | 23 | 1.340 |
Why?
|
| Translocation, Genetic | 39 | 2021 | 263 | 1.290 |
Why?
|
| Arabinonucleosides | 7 | 2013 | 39 | 1.240 |
Why?
|
| Young Adult | 81 | 2025 | 7025 | 1.210 |
Why?
|
| Drug Administration Schedule | 43 | 2019 | 873 | 1.210 |
Why?
|
| Antibodies, Monoclonal | 20 | 2010 | 1431 | 1.140 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 65 | 1.120 |
Why?
|
| Hematologic Neoplasms | 15 | 2023 | 372 | 1.100 |
Why?
|
| Drug Resistance, Neoplasm | 29 | 2024 | 647 | 1.100 |
Why?
|
| Follow-Up Studies | 52 | 2024 | 3927 | 1.090 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2024 | 1469 | 1.080 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2022 | 303 | 1.070 |
Why?
|
| Aminoglycosides | 9 | 2014 | 31 | 1.060 |
Why?
|
| Acute Disease | 67 | 2022 | 872 | 1.040 |
Why?
|
| Nuclear Proteins | 16 | 2020 | 750 | 1.000 |
Why?
|
| Philadelphia Chromosome | 9 | 2021 | 44 | 0.980 |
Why?
|
| Sarcoma, Myeloid | 4 | 2015 | 14 | 0.980 |
Why?
|
| Tandem Repeat Sequences | 7 | 2021 | 31 | 0.970 |
Why?
|
| Chromosomes, Human, Pair 5 | 19 | 2021 | 115 | 0.960 |
Why?
|
| Biomarkers, Tumor | 23 | 2025 | 1665 | 0.960 |
Why?
|
| Gene Expression Profiling | 32 | 2016 | 1534 | 0.960 |
Why?
|
| Clinical Trials as Topic | 26 | 2022 | 1178 | 0.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2025 | 1020 | 0.880 |
Why?
|
| Lymphoma | 9 | 2023 | 271 | 0.870 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2018 | 99 | 0.840 |
Why?
|
| Salvage Therapy | 13 | 2021 | 238 | 0.830 |
Why?
|
| Induction Chemotherapy | 8 | 2019 | 151 | 0.830 |
Why?
|
| Age Factors | 33 | 2025 | 1963 | 0.830 |
Why?
|
| Immunotherapy | 10 | 2023 | 763 | 0.820 |
Why?
|
| Recurrence | 35 | 2022 | 1218 | 0.820 |
Why?
|
| Asparaginase | 6 | 2023 | 35 | 0.780 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 61 | 0.780 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 58 | 0.760 |
Why?
|
| Antibodies, Neoplasm | 9 | 2010 | 86 | 0.760 |
Why?
|
| Aniline Compounds | 6 | 2023 | 63 | 0.750 |
Why?
|
| Myeloproliferative Disorders | 7 | 2024 | 145 | 0.740 |
Why?
|
| Graft vs Host Disease | 17 | 2020 | 368 | 0.730 |
Why?
|
| Disease Management | 10 | 2025 | 360 | 0.720 |
Why?
|
| Neoplasm Proteins | 20 | 2012 | 554 | 0.720 |
Why?
|
| Cytosine | 4 | 2018 | 135 | 0.710 |
Why?
|
| Kaplan-Meier Estimate | 33 | 2024 | 886 | 0.710 |
Why?
|
| Bone Marrow Transplantation | 15 | 2006 | 294 | 0.710 |
Why?
|
| Adenine Nucleotides | 4 | 2013 | 63 | 0.690 |
Why?
|
| Antibodies, Bispecific | 5 | 2021 | 37 | 0.680 |
Why?
|
| Mitoxantrone | 11 | 2020 | 68 | 0.670 |
Why?
|
| Piperidines | 8 | 2024 | 171 | 0.660 |
Why?
|
| Cladribine | 6 | 2004 | 35 | 0.650 |
Why?
|
| Geriatric Assessment | 5 | 2022 | 192 | 0.650 |
Why?
|
| Bone Marrow | 37 | 2018 | 458 | 0.650 |
Why?
|
| Interferon-alpha | 13 | 2017 | 215 | 0.640 |
Why?
|
| Combined Modality Therapy | 23 | 2021 | 1773 | 0.640 |
Why?
|
| Antimetabolites, Antineoplastic | 11 | 2024 | 244 | 0.640 |
Why?
|
| Alemtuzumab | 14 | 2025 | 90 | 0.630 |
Why?
|
| Cytogenetic Analysis | 18 | 2017 | 72 | 0.610 |
Why?
|
| Pyrazines | 5 | 2023 | 94 | 0.610 |
Why?
|
| Dose-Response Relationship, Drug | 26 | 2021 | 1973 | 0.600 |
Why?
|
| Tretinoin | 10 | 2020 | 131 | 0.580 |
Why?
|
| Drugs, Generic | 2 | 2016 | 21 | 0.570 |
Why?
|
| Intestinal Absorption | 2 | 2017 | 126 | 0.560 |
Why?
|
| Valine | 2 | 2016 | 62 | 0.560 |
Why?
|
| Rituximab | 13 | 2024 | 133 | 0.560 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2024 | 2473 | 0.550 |
Why?
|
| Respiratory Tract Infections | 3 | 2015 | 117 | 0.550 |
Why?
|
| Chromosome Deletion | 20 | 2014 | 229 | 0.550 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2025 | 465 | 0.550 |
Why?
|
| Acyclovir | 2 | 2016 | 110 | 0.540 |
Why?
|
| Chromosomes, Human, Pair 7 | 9 | 2014 | 81 | 0.530 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 11 | 2013 | 76 | 0.530 |
Why?
|
| Carbonated Beverages | 1 | 2017 | 2 | 0.530 |
Why?
|
| Herpes Zoster | 3 | 2016 | 80 | 0.520 |
Why?
|
| Precision Medicine | 2 | 2019 | 451 | 0.520 |
Why?
|
| Drug Monitoring | 5 | 2021 | 120 | 0.510 |
Why?
|
| Immunotoxins | 4 | 2012 | 16 | 0.510 |
Why?
|
| Prospective Studies | 34 | 2024 | 4671 | 0.510 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2012 | 96 | 0.510 |
Why?
|
| Medical Oncology | 4 | 2021 | 408 | 0.510 |
Why?
|
| DNA-Binding Proteins | 20 | 2016 | 1268 | 0.500 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 39 | 0.500 |
Why?
|
| Organophosphonates | 1 | 2016 | 53 | 0.500 |
Why?
|
| Proton Pump Inhibitors | 2 | 2017 | 34 | 0.490 |
Why?
|
| Stem Cell Transplantation | 10 | 2020 | 192 | 0.490 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 38 | 0.490 |
Why?
|
| Leukemia, Radiation-Induced | 2 | 2015 | 14 | 0.480 |
Why?
|
| Pyrazoles | 4 | 2024 | 161 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 15 | 2018 | 684 | 0.480 |
Why?
|
| Adenine | 5 | 2024 | 92 | 0.480 |
Why?
|
| Etoposide | 15 | 2013 | 212 | 0.460 |
Why?
|
| Sulfonamides | 4 | 2025 | 338 | 0.460 |
Why?
|
| Neoplasm, Residual | 8 | 2022 | 194 | 0.460 |
Why?
|
| Maintenance Chemotherapy | 4 | 2021 | 91 | 0.460 |
Why?
|
| Karyotyping | 41 | 2014 | 257 | 0.460 |
Why?
|
| Neutropenia | 10 | 2010 | 218 | 0.460 |
Why?
|
| Oxides | 3 | 2014 | 44 | 0.460 |
Why?
|
| Thrombocytopenia | 9 | 2017 | 191 | 0.450 |
Why?
|
| Arsenicals | 3 | 2014 | 49 | 0.450 |
Why?
|
| Time Factors | 35 | 2015 | 5585 | 0.450 |
Why?
|
| Multivariate Analysis | 22 | 2020 | 1010 | 0.450 |
Why?
|
| Models, Economic | 1 | 2015 | 62 | 0.440 |
Why?
|
| Quality of Life | 8 | 2022 | 1816 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 305 | 0.440 |
Why?
|
| Thiazoles | 9 | 2013 | 130 | 0.430 |
Why?
|
| Neoplasms | 13 | 2022 | 3250 | 0.430 |
Why?
|
| Antiviral Agents | 2 | 2016 | 504 | 0.430 |
Why?
|
| Polyethylene Glycols | 5 | 2023 | 377 | 0.430 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2023 | 62 | 0.420 |
Why?
|
| Drug Resistance, Multiple | 4 | 2008 | 20 | 0.420 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2025 | 103 | 0.420 |
Why?
|
| Abnormal Karyotype | 2 | 2013 | 8 | 0.410 |
Why?
|
| Risk Factors | 35 | 2024 | 5960 | 0.400 |
Why?
|
| Disease Progression | 20 | 2017 | 1568 | 0.400 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2016 | 91 | 0.400 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2014 | 104 | 0.400 |
Why?
|
| Lung Diseases | 2 | 2014 | 290 | 0.390 |
Why?
|
| Infusions, Intravenous | 18 | 2014 | 423 | 0.390 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 354 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 21 | 11 | 2015 | 54 | 0.390 |
Why?
|
| Cyclosporins | 6 | 2013 | 56 | 0.390 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 4 | 2010 | 7 | 0.380 |
Why?
|
| Histamine H2 Antagonists | 1 | 2012 | 13 | 0.380 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2025 | 226 | 0.370 |
Why?
|
| HLA Antigens | 3 | 2021 | 231 | 0.370 |
Why?
|
| Risk Assessment | 16 | 2024 | 2480 | 0.370 |
Why?
|
| Immunophenotyping | 14 | 2019 | 226 | 0.370 |
Why?
|
| Proportional Hazards Models | 18 | 2020 | 901 | 0.370 |
Why?
|
| Aminopyridines | 2 | 2023 | 49 | 0.360 |
Why?
|
| Triazines | 2 | 2023 | 55 | 0.360 |
Why?
|
| DNA Mutational Analysis | 13 | 2016 | 547 | 0.360 |
Why?
|
| Bortezomib | 3 | 2018 | 82 | 0.360 |
Why?
|
| Burkitt Lymphoma | 4 | 2014 | 34 | 0.350 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 2007 | 16 | 0.350 |
Why?
|
| Methotrexate | 9 | 2015 | 249 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 11 | 9 | 2006 | 107 | 0.340 |
Why?
|
| Clinical Trials, Phase II as Topic | 9 | 2016 | 172 | 0.340 |
Why?
|
| United States | 27 | 2025 | 7767 | 0.340 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 1993 | 114 | 0.340 |
Why?
|
| Antigens, CD | 6 | 2009 | 482 | 0.340 |
Why?
|
| Mutation, Missense | 3 | 2014 | 302 | 0.340 |
Why?
|
| Blast Crisis | 10 | 2013 | 37 | 0.340 |
Why?
|
| Radiotherapy | 8 | 2009 | 328 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 10 | 2014 | 81 | 0.330 |
Why?
|
| Leukemia, B-Cell | 5 | 2002 | 23 | 0.330 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2016 | 327 | 0.330 |
Why?
|
| Retrospective Studies | 26 | 2024 | 10286 | 0.330 |
Why?
|
| Quinolones | 3 | 2021 | 57 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 935 | 0.330 |
Why?
|
| RNA, Neoplasm | 5 | 2018 | 89 | 0.330 |
Why?
|
| Child | 34 | 2023 | 7626 | 0.320 |
Why?
|
| Interleukin-2 | 5 | 2013 | 248 | 0.320 |
Why?
|
| Cytogenetics | 8 | 2022 | 28 | 0.320 |
Why?
|
| Gene Dosage | 2 | 2012 | 212 | 0.320 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2023 | 4 | 0.320 |
Why?
|
| Myeloid Cells | 1 | 2010 | 121 | 0.310 |
Why?
|
| Oncogene Proteins, Fusion | 7 | 2016 | 134 | 0.310 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 4 | 2005 | 32 | 0.310 |
Why?
|
| Polymorphism, Genetic | 4 | 2016 | 829 | 0.310 |
Why?
|
| Cyclophosphamide | 12 | 2015 | 313 | 0.310 |
Why?
|
| Health Status | 1 | 2011 | 386 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2015 | 466 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 4 | 2002 | 847 | 0.300 |
Why?
|
| Neoplastic Stem Cells | 5 | 2016 | 174 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 299 | 0.300 |
Why?
|
| Enzyme Inhibitors | 5 | 2023 | 657 | 0.290 |
Why?
|
| Lymphoma, Non-Hodgkin | 11 | 2011 | 271 | 0.290 |
Why?
|
| Transplantation, Autologous | 9 | 2019 | 362 | 0.290 |
Why?
|
| Hodgkin Disease | 8 | 2007 | 170 | 0.290 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 107 | 0.290 |
Why?
|
| Adolescent Behavior | 3 | 2001 | 115 | 0.280 |
Why?
|
| Thrombopoietin | 4 | 2017 | 12 | 0.280 |
Why?
|
| Cohort Studies | 14 | 2021 | 3107 | 0.280 |
Why?
|
| Hematologic Agents | 3 | 2017 | 4 | 0.280 |
Why?
|
| Neoplasm Staging | 15 | 2018 | 2081 | 0.280 |
Why?
|
| Chromosome Inversion | 9 | 2012 | 48 | 0.280 |
Why?
|
| Purine Nucleosides | 1 | 2007 | 7 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 16 | 7 | 2004 | 79 | 0.280 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2007 | 20 | 0.280 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 392 | 0.270 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 12 | 2012 | 701 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2494 | 0.270 |
Why?
|
| Antigens, CD34 | 9 | 2017 | 163 | 0.270 |
Why?
|
| Pyrimidinones | 1 | 2007 | 44 | 0.270 |
Why?
|
| Gene Duplication | 3 | 2020 | 129 | 0.270 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 4 | 2012 | 67 | 0.270 |
Why?
|
| Trans-Activators | 8 | 2018 | 447 | 0.260 |
Why?
|
| Incidence | 11 | 2022 | 1715 | 0.260 |
Why?
|
| Treatment Failure | 8 | 2015 | 297 | 0.260 |
Why?
|
| Bone Marrow Cells | 4 | 2014 | 279 | 0.260 |
Why?
|
| Busulfan | 5 | 2015 | 43 | 0.260 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2016 | 169 | 0.260 |
Why?
|
| Asparagine | 1 | 2007 | 29 | 0.260 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 23 | 0.260 |
Why?
|
| Hypertension | 2 | 2024 | 777 | 0.250 |
Why?
|
| Injections, Subcutaneous | 7 | 2024 | 134 | 0.250 |
Why?
|
| Karyotype | 3 | 2022 | 34 | 0.250 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 17 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 9 | 2012 | 930 | 0.250 |
Why?
|
| Gene Rearrangement | 10 | 2012 | 179 | 0.250 |
Why?
|
| Feasibility Studies | 5 | 2009 | 819 | 0.250 |
Why?
|
| Child Behavior | 2 | 2001 | 47 | 0.250 |
Why?
|
| Transcription Factors | 14 | 2018 | 1730 | 0.250 |
Why?
|
| Bendamustine Hydrochloride | 3 | 2024 | 12 | 0.250 |
Why?
|
| Multicenter Studies as Topic | 8 | 2022 | 183 | 0.240 |
Why?
|
| Biological Availability | 4 | 2017 | 89 | 0.240 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2010 | 898 | 0.240 |
Why?
|
| Maximum Tolerated Dose | 10 | 2017 | 270 | 0.240 |
Why?
|
| Carcinogens | 3 | 2002 | 106 | 0.240 |
Why?
|
| Europe | 9 | 2025 | 349 | 0.230 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2018 | 61 | 0.230 |
Why?
|
| DNA, Neoplasm | 10 | 2003 | 272 | 0.230 |
Why?
|
| Child, Preschool | 18 | 2018 | 3974 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 8 | 8 | 2015 | 83 | 0.230 |
Why?
|
| Leukemia, Lymphoid | 6 | 1985 | 71 | 0.230 |
Why?
|
| Chromosome Disorders | 15 | 1999 | 112 | 0.230 |
Why?
|
| Societies, Medical | 3 | 2019 | 644 | 0.230 |
Why?
|
| Administration, Oral | 13 | 2019 | 688 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2017 | 564 | 0.220 |
Why?
|
| Thionucleotides | 4 | 2021 | 56 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2016 | 647 | 0.220 |
Why?
|
| Flavonoids | 3 | 2015 | 85 | 0.220 |
Why?
|
| Mevalonic Acid | 5 | 1984 | 13 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2012 | 301 | 0.220 |
Why?
|
| Melphalan | 5 | 2023 | 100 | 0.220 |
Why?
|
| Risk | 8 | 2014 | 668 | 0.220 |
Why?
|
| Dexamethasone | 3 | 2021 | 351 | 0.220 |
Why?
|
| Down-Regulation | 7 | 2016 | 527 | 0.220 |
Why?
|
| Drug Costs | 2 | 2015 | 68 | 0.220 |
Why?
|
| Drug Hypersensitivity | 2 | 1998 | 40 | 0.220 |
Why?
|
| Doxorubicin | 10 | 2015 | 304 | 0.210 |
Why?
|
| Primary Myelofibrosis | 1 | 2024 | 68 | 0.210 |
Why?
|
| CD47 Antigen | 1 | 2024 | 24 | 0.210 |
Why?
|
| Haplotypes | 3 | 2016 | 650 | 0.210 |
Why?
|
| Mammary Glands, Human | 1 | 2023 | 26 | 0.210 |
Why?
|
| Allografts | 3 | 2019 | 207 | 0.210 |
Why?
|
| Phthalazines | 2 | 2014 | 53 | 0.200 |
Why?
|
| Leukocyte Count | 8 | 2024 | 228 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2013 | 80 | 0.200 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2016 | 157 | 0.200 |
Why?
|
| Deoxycytidine | 1 | 2004 | 215 | 0.200 |
Why?
|
| Ricin | 1 | 2003 | 6 | 0.200 |
Why?
|
| Neutrophils | 8 | 2016 | 334 | 0.200 |
Why?
|
| Pyridines | 3 | 2014 | 319 | 0.200 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2014 | 100 | 0.190 |
Why?
|
| Whole-Body Irradiation | 2 | 2000 | 70 | 0.190 |
Why?
|
| Mycoses | 4 | 2007 | 47 | 0.190 |
Why?
|
| Musculoskeletal Pain | 1 | 2022 | 11 | 0.190 |
Why?
|
| Recombinant Proteins | 11 | 2014 | 1034 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2023 | 70 | 0.190 |
Why?
|
| Eosinophils | 4 | 1995 | 199 | 0.190 |
Why?
|
| Gene Expression | 9 | 2020 | 1322 | 0.190 |
Why?
|
| Vincristine | 7 | 2016 | 113 | 0.190 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2016 | 184 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2013 | 1351 | 0.190 |
Why?
|
| Histocompatibility Testing | 4 | 2017 | 141 | 0.190 |
Why?
|
| Antigens, Neoplasm | 4 | 2009 | 359 | 0.180 |
Why?
|
| Dinitrobenzenes | 1 | 2002 | 5 | 0.180 |
Why?
|
| Escherichia coli | 6 | 2000 | 627 | 0.180 |
Why?
|
| Immunoconjugates | 1 | 2003 | 131 | 0.180 |
Why?
|
| Unrelated Donors | 3 | 2017 | 47 | 0.180 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 6 | 2011 | 38 | 0.180 |
Why?
|
| Animals | 19 | 2023 | 28945 | 0.180 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 32 | 0.180 |
Why?
|
| Surface-Active Agents | 1 | 2002 | 62 | 0.180 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 639 | 0.180 |
Why?
|
| Topotecan | 3 | 2009 | 46 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2006 | 441 | 0.180 |
Why?
|
| T-Lymphocytes | 6 | 2023 | 1316 | 0.180 |
Why?
|
| Sex Characteristics | 1 | 2023 | 339 | 0.180 |
Why?
|
| Phenotype | 7 | 2019 | 2579 | 0.170 |
Why?
|
| DNA Damage | 3 | 2013 | 392 | 0.170 |
Why?
|
| Clonal Evolution | 1 | 2021 | 17 | 0.170 |
Why?
|
| Genes, Wilms Tumor | 3 | 2010 | 6 | 0.170 |
Why?
|
| Bone Marrow Diseases | 4 | 2009 | 40 | 0.170 |
Why?
|
| Proto-Oncogenes | 6 | 2013 | 61 | 0.170 |
Why?
|
| Agranulocytosis | 2 | 1993 | 20 | 0.170 |
Why?
|
| Evidence-Based Medicine | 4 | 2015 | 458 | 0.170 |
Why?
|
| Social Isolation | 2 | 1996 | 70 | 0.170 |
Why?
|
| Mutagenesis, Insertional | 1 | 2021 | 116 | 0.170 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1619 | 0.170 |
Why?
|
| Mass Media | 1 | 2001 | 27 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 3 | 5 | 2002 | 54 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 4 | 2014 | 119 | 0.170 |
Why?
|
| Homeodomain Proteins | 5 | 2014 | 563 | 0.170 |
Why?
|
| Fatigue | 4 | 2010 | 185 | 0.170 |
Why?
|
| Immunosuppressive Agents | 5 | 2015 | 995 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2016 | 52 | 0.160 |
Why?
|
| Gene Deletion | 2 | 2016 | 358 | 0.160 |
Why?
|
| Quinolines | 2 | 2020 | 89 | 0.160 |
Why?
|
| Codon | 2 | 2016 | 120 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2022 | 209 | 0.160 |
Why?
|
| Point Mutation | 2 | 2007 | 247 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 4 | 2021 | 1096 | 0.160 |
Why?
|
| Trisomy | 7 | 2012 | 56 | 0.160 |
Why?
|
| Microarray Analysis | 3 | 2014 | 98 | 0.160 |
Why?
|
| Chromatography, High Pressure Liquid | 7 | 2006 | 311 | 0.160 |
Why?
|
| Clinical Protocols | 3 | 2018 | 162 | 0.160 |
Why?
|
| Cell Cycle Proteins | 4 | 2018 | 412 | 0.160 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1999 | 10 | 0.160 |
Why?
|
| Area Under Curve | 4 | 2014 | 340 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2008 | 114 | 0.150 |
Why?
|
| Genotype | 7 | 2021 | 1882 | 0.150 |
Why?
|
| Caregivers | 1 | 2001 | 185 | 0.150 |
Why?
|
| Immunocompromised Host | 3 | 2016 | 147 | 0.150 |
Why?
|
| Fetal Blood | 2 | 2017 | 96 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 135 | 0.150 |
Why?
|
| Expert Testimony | 1 | 2018 | 34 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 813 | 0.140 |
Why?
|
| Anemia | 3 | 2010 | 137 | 0.140 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2016 | 91 | 0.140 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 6 | 2012 | 60 | 0.140 |
Why?
|
| Inflammation | 1 | 2024 | 1068 | 0.140 |
Why?
|
| Lymphoproliferative Disorders | 2 | 1996 | 109 | 0.140 |
Why?
|
| Ultraviolet Rays | 4 | 2002 | 198 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2015 | 366 | 0.140 |
Why?
|
| Hematopoiesis | 5 | 2016 | 183 | 0.140 |
Why?
|
| Esophageal Cyst | 1 | 1998 | 3 | 0.140 |
Why?
|
| Mastocytosis, Systemic | 1 | 2018 | 13 | 0.140 |
Why?
|
| Logistic Models | 8 | 2015 | 1268 | 0.140 |
Why?
|
| Graft Survival | 4 | 2016 | 942 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2017 | 294 | 0.140 |
Why?
|
| Drug Approval | 3 | 2018 | 69 | 0.140 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 3 | 2015 | 18 | 0.140 |
Why?
|
| Patient Participation | 2 | 2022 | 241 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 9 | 2012 | 165 | 0.140 |
Why?
|
| DNA Methylation | 5 | 2015 | 703 | 0.140 |
Why?
|
| CD52 Antigen | 2 | 2025 | 6 | 0.140 |
Why?
|
| Mercaptopurine | 3 | 2014 | 53 | 0.140 |
Why?
|
| Leukemic Infiltration | 2 | 2007 | 14 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2012 | 152 | 0.130 |
Why?
|
| Receptors, Fc | 3 | 2017 | 40 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2018 | 71 | 0.130 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 381 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2006 | 128 | 0.130 |
Why?
|
| Injections, Spinal | 1 | 2017 | 50 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 4 | 2006 | 80 | 0.130 |
Why?
|
| Microsatellite Repeats | 2 | 2000 | 151 | 0.130 |
Why?
|
| Life Tables | 5 | 2003 | 47 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 418 | 0.130 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 4 | 2005 | 8 | 0.130 |
Why?
|
| Stress, Psychological | 2 | 2001 | 345 | 0.130 |
Why?
|
| Lymphocyte Activation | 4 | 1984 | 810 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 404 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2019 | 307 | 0.130 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 156 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.130 |
Why?
|
| Pilot Projects | 9 | 2020 | 938 | 0.130 |
Why?
|
| Investigational New Drug Application | 1 | 2016 | 2 | 0.130 |
Why?
|
| Foscarnet | 1 | 2016 | 11 | 0.130 |
Why?
|
| Hematologic Diseases | 6 | 2018 | 79 | 0.130 |
Why?
|
| Amphotericin B | 3 | 1993 | 37 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 490 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 2 | 2009 | 155 | 0.130 |
Why?
|
| WT1 Proteins | 3 | 2011 | 21 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2020 | 594 | 0.130 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 48 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 228 | 0.130 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 49 | 0.130 |
Why?
|
| Telomere Homeostasis | 1 | 2016 | 30 | 0.120 |
Why?
|
| Cell Dedifferentiation | 1 | 2016 | 10 | 0.120 |
Why?
|
| Blood Donors | 1 | 2016 | 24 | 0.120 |
Why?
|
| Survivors | 2 | 2015 | 204 | 0.120 |
Why?
|
| Lymphocytes | 7 | 1990 | 489 | 0.120 |
Why?
|
| Comorbidity | 5 | 2022 | 1011 | 0.120 |
Why?
|
| Predictive Value of Tests | 11 | 2014 | 1807 | 0.120 |
Why?
|
| Telomerase | 1 | 2016 | 68 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 30 | 0.120 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.120 |
Why?
|
| Leukemia, Prolymphocytic | 2 | 2012 | 3 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2004 | 138 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2014 | 209 | 0.120 |
Why?
|
| Ikaros Transcription Factor | 1 | 2016 | 25 | 0.120 |
Why?
|
| Age Distribution | 2 | 2008 | 209 | 0.120 |
Why?
|
| Repressor Proteins | 3 | 2018 | 447 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 91 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 84 | 0.120 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 44 | 0.120 |
Why?
|
| Cell Differentiation | 6 | 2016 | 1666 | 0.120 |
Why?
|
| Physicians | 2 | 2022 | 707 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 67 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 187 | 0.120 |
Why?
|
| Prescription Fees | 1 | 2015 | 10 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2019 | 1423 | 0.120 |
Why?
|
| Gene Frequency | 5 | 2016 | 703 | 0.120 |
Why?
|
| Genes, ras | 3 | 2013 | 97 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 8 | 2021 | 1054 | 0.120 |
Why?
|
| CpG Islands | 2 | 2015 | 169 | 0.120 |
Why?
|
| Health Impact Assessment | 1 | 2015 | 2 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.120 |
Why?
|
| European Union | 1 | 2015 | 8 | 0.120 |
Why?
|
| Azocines | 1 | 2015 | 3 | 0.110 |
Why?
|
| Graft Rejection | 2 | 2016 | 1126 | 0.110 |
Why?
|
| Patents as Topic | 1 | 2015 | 12 | 0.110 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1995 | 5 | 0.110 |
Why?
|
| Chromosome Mapping | 15 | 2003 | 1083 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 5 | 2015 | 129 | 0.110 |
Why?
|
| Registries | 2 | 2022 | 986 | 0.110 |
Why?
|
| Core Binding Factors | 3 | 2011 | 12 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 1995 | 38 | 0.110 |
Why?
|
| Sulfonic Acids | 1 | 1995 | 9 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 1998 | 346 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 34 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 1996 | 174 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 45 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2015 | 65 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 162 | 0.110 |
Why?
|
| Apoptosis | 6 | 2016 | 1763 | 0.110 |
Why?
|
| Cost Savings | 1 | 2015 | 71 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 52 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 192 | 0.110 |
Why?
|
| Pyridazines | 1 | 2014 | 22 | 0.110 |
Why?
|
| Transcriptional Regulator ERG | 6 | 2010 | 17 | 0.110 |
Why?
|
| Karnofsky Performance Status | 2 | 2006 | 44 | 0.110 |
Why?
|
| Laboratory Chemicals | 1 | 2014 | 1 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 79 | 0.110 |
Why?
|
| DNA | 9 | 2007 | 1332 | 0.110 |
Why?
|
| Farnesyltranstransferase | 1 | 2013 | 7 | 0.110 |
Why?
|
| Fusarium | 2 | 1993 | 5 | 0.100 |
Why?
|
| Cell Survival | 3 | 2013 | 1032 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2022 | 178 | 0.100 |
Why?
|
| Cytochalasin B | 2 | 1983 | 19 | 0.100 |
Why?
|
| Stem Cell Niche | 1 | 2014 | 24 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2012 | 318 | 0.100 |
Why?
|
| Cell Cycle | 9 | 2010 | 518 | 0.100 |
Why?
|
| Social Support | 1 | 1996 | 239 | 0.100 |
Why?
|
| Simvastatin | 1 | 2014 | 106 | 0.100 |
Why?
|
| Imidazoles | 1 | 2014 | 145 | 0.100 |
Why?
|
| Adenosine | 1 | 2016 | 278 | 0.100 |
Why?
|
| Cell Lineage | 5 | 2002 | 324 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2005 | 109 | 0.100 |
Why?
|
| Nausea | 3 | 2010 | 182 | 0.100 |
Why?
|
| Oncogenes | 3 | 2010 | 100 | 0.100 |
Why?
|
| Brain Diseases | 1 | 1995 | 192 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2015 | 369 | 0.100 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 176 | 0.100 |
Why?
|
| Drug Resistance | 7 | 2007 | 237 | 0.100 |
Why?
|
| Blood Component Transfusion | 1 | 1993 | 13 | 0.100 |
Why?
|
| Topoisomerase II Inhibitors | 3 | 2000 | 28 | 0.100 |
Why?
|
| Body Surface Area | 2 | 2015 | 37 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2013 | 98 | 0.100 |
Why?
|
| Iron | 2 | 2001 | 179 | 0.100 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2012 | 20 | 0.100 |
Why?
|
| Base Sequence | 9 | 2012 | 2344 | 0.100 |
Why?
|
| Amsacrine | 1 | 1992 | 3 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 112 | 0.100 |
Why?
|
| Peripheral Nervous System | 1 | 2012 | 21 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2012 | 245 | 0.100 |
Why?
|
| Sex Factors | 5 | 2008 | 1133 | 0.100 |
Why?
|
| Dioxolanes | 2 | 2003 | 8 | 0.100 |
Why?
|
| Hypohidrosis | 1 | 2012 | 2 | 0.100 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2003 | 22 | 0.100 |
Why?
|
| Alopecia Areata | 1 | 2012 | 5 | 0.100 |
Why?
|
| Blood Component Removal | 2 | 2008 | 28 | 0.100 |
Why?
|
| Hypopigmentation | 1 | 2012 | 5 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 55 | 0.100 |
Why?
|
| Haemophilus influenzae | 1 | 1992 | 17 | 0.090 |
Why?
|
| Obesity | 2 | 2019 | 1034 | 0.090 |
Why?
|
| Listeriosis | 1 | 1993 | 90 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 908 | 0.090 |
Why?
|
| Lung Diseases, Fungal | 2 | 1992 | 18 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 1992 | 253 | 0.090 |
Why?
|
| Hypotension | 2 | 2009 | 76 | 0.090 |
Why?
|
| Monitoring, Physiologic | 3 | 2020 | 273 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2018 | 3586 | 0.090 |
Why?
|
| DNA Repair | 2 | 2013 | 376 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 3 | 2004 | 41 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2012 | 173 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 180 | 0.090 |
Why?
|
| Statistics, Nonparametric | 6 | 2008 | 311 | 0.090 |
Why?
|
| Chlorambucil | 4 | 2012 | 23 | 0.090 |
Why?
|
| Mastectomy | 1 | 2014 | 270 | 0.090 |
Why?
|
| North America | 2 | 2010 | 199 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2004 | 159 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 271 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 2794 | 0.090 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 18 | 0.090 |
Why?
|
| Alkylating Agents | 2 | 2009 | 32 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2018 | 327 | 0.090 |
Why?
|
| Mice | 9 | 2023 | 12562 | 0.090 |
Why?
|
| Child Development | 2 | 1991 | 174 | 0.090 |
Why?
|
| Drug Tolerance | 2 | 2010 | 64 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2007 | 156 | 0.090 |
Why?
|
| Methyltransferases | 5 | 2018 | 213 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 1998 | 1215 | 0.090 |
Why?
|
| Genetic Markers | 7 | 2008 | 479 | 0.090 |
Why?
|
| Leukocytosis | 2 | 2007 | 15 | 0.090 |
Why?
|
| Infant | 6 | 2018 | 3363 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 12 | 4 | 1998 | 65 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2021 | 1958 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 1991 | 89 | 0.080 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2011 | 9 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2010 | 37 | 0.080 |
Why?
|
| Social Behavior | 2 | 1991 | 309 | 0.080 |
Why?
|
| Epigenomics | 1 | 2011 | 107 | 0.080 |
Why?
|
| Chromosomes, Human, 16-18 | 3 | 1984 | 26 | 0.080 |
Why?
|
| Aging | 2 | 2012 | 766 | 0.080 |
Why?
|
| Cross-Over Studies | 5 | 2017 | 397 | 0.080 |
Why?
|
| Filgrastim | 3 | 2014 | 59 | 0.080 |
Why?
|
| Granulocytes | 2 | 1993 | 41 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2013 | 432 | 0.080 |
Why?
|
| Electroencephalography | 1 | 1995 | 824 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 305 | 0.080 |
Why?
|
| Immunologic Factors | 3 | 2005 | 179 | 0.080 |
Why?
|
| DNA Probes | 2 | 2008 | 77 | 0.080 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 216 | 0.080 |
Why?
|
| Psychology, Adolescent | 1 | 1989 | 29 | 0.080 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 84 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1276 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2002 | 51 | 0.080 |
Why?
|
| Glutathione | 1 | 2009 | 107 | 0.070 |
Why?
|
| Prodrugs | 1 | 2009 | 54 | 0.070 |
Why?
|
| Carbolines | 1 | 1988 | 8 | 0.070 |
Why?
|
| Lepidoptera | 1 | 1988 | 15 | 0.070 |
Why?
|
| Idarubicin | 2 | 2023 | 8 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 96 | 0.070 |
Why?
|
| International Cooperation | 3 | 2016 | 134 | 0.070 |
Why?
|
| Alkaloids | 1 | 1988 | 47 | 0.070 |
Why?
|
| Platelet Count | 4 | 2017 | 97 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2008 | 32 | 0.070 |
Why?
|
| Cause of Death | 2 | 2018 | 278 | 0.070 |
Why?
|
| Skin | 2 | 2007 | 605 | 0.070 |
Why?
|
| Dioxygenases | 3 | 2016 | 82 | 0.070 |
Why?
|
| Models, Biological | 2 | 2014 | 1815 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2012 | 542 | 0.070 |
Why?
|
| Splenomegaly | 2 | 2006 | 29 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2009 | 233 | 0.070 |
Why?
|
| Chromosomes, Human | 4 | 2003 | 67 | 0.070 |
Why?
|
| Genes, abl | 2 | 2010 | 12 | 0.070 |
Why?
|
| Epigenesis, Genetic | 4 | 2016 | 554 | 0.070 |
Why?
|
| Emotions | 2 | 1989 | 377 | 0.070 |
Why?
|
| United States Food and Drug Administration | 3 | 2018 | 147 | 0.070 |
Why?
|
| Blood Platelets | 2 | 2017 | 156 | 0.070 |
Why?
|
| Genital Neoplasms, Male | 1 | 1988 | 11 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2008 | 34 | 0.070 |
Why?
|
| Chimerism | 2 | 2020 | 38 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 51 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 1981 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 828 | 0.070 |
Why?
|
| Scrotum | 1 | 1988 | 18 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 286 | 0.070 |
Why?
|
| Up-Regulation | 4 | 2014 | 741 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 122 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 206 | 0.070 |
Why?
|
| Hemangioma | 1 | 1988 | 65 | 0.070 |
Why?
|
| Uveitis | 1 | 2007 | 35 | 0.070 |
Why?
|
| Diarrhea | 3 | 2012 | 181 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 189 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 296 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 342 | 0.070 |
Why?
|
| Leiomyosarcoma | 1 | 1988 | 49 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 276 | 0.070 |
Why?
|
| Consensus | 2 | 2021 | 370 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 281 | 0.070 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 23 | 0.070 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 28 | 0.070 |
Why?
|
| Rubber | 2 | 1996 | 6 | 0.060 |
Why?
|
| Liver | 3 | 2019 | 1238 | 0.060 |
Why?
|
| Butadienes | 2 | 1996 | 34 | 0.060 |
Why?
|
| DNA Replication | 3 | 1989 | 177 | 0.060 |
Why?
|
| Alleles | 4 | 2011 | 1157 | 0.060 |
Why?
|
| Retreatment | 2 | 2017 | 106 | 0.060 |
Why?
|
| Blotting, Southern | 3 | 2003 | 128 | 0.060 |
Why?
|
| Body Weight | 1 | 2008 | 460 | 0.060 |
Why?
|
| Methylation | 2 | 2018 | 295 | 0.060 |
Why?
|
| Chromosome Breakage | 2 | 2003 | 17 | 0.060 |
Why?
|
| Genomics | 2 | 2022 | 855 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 2 | 1998 | 46 | 0.060 |
Why?
|
| Anthracyclines | 2 | 2019 | 38 | 0.060 |
Why?
|
| Occupational Diseases | 2 | 1996 | 57 | 0.060 |
Why?
|
| Blood Cell Count | 5 | 2007 | 79 | 0.060 |
Why?
|
| Pneumonia | 1 | 1988 | 197 | 0.060 |
Why?
|
| Prevalence | 2 | 2022 | 1349 | 0.060 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2006 | 11 | 0.060 |
Why?
|
| Aminopterin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ganciclovir | 1 | 2006 | 52 | 0.060 |
Why?
|
| RNA, Messenger | 6 | 2010 | 2092 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 81 | 0.060 |
Why?
|
| Folic Acid Antagonists | 1 | 2005 | 17 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2022 | 565 | 0.060 |
Why?
|
| Health Planning Guidelines | 2 | 2019 | 22 | 0.060 |
Why?
|
| Germany | 1 | 2025 | 80 | 0.060 |
Why?
|
| Placebos | 2 | 2012 | 213 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2005 | 239 | 0.060 |
Why?
|
| Chromosomes, Artificial, Yeast | 3 | 2000 | 36 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2005 | 162 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2006 | 182 | 0.060 |
Why?
|
| Xylose | 1 | 1984 | 24 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2009 | 632 | 0.060 |
Why?
|
| Hyperphagia | 1 | 1985 | 35 | 0.060 |
Why?
|
| Stomatitis | 2 | 2000 | 30 | 0.060 |
Why?
|
| Chromosome Banding | 7 | 2000 | 73 | 0.060 |
Why?
|
| DNA Primers | 3 | 2006 | 548 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2002 | 102 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2002 | 66 | 0.050 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 3041 | 0.050 |
Why?
|
| Forecasting | 2 | 2004 | 317 | 0.050 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 1984 | 32 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2007 | 205 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 363 | 0.050 |
Why?
|
| Kinetics | 4 | 2002 | 1562 | 0.050 |
Why?
|
| Niacinamide | 1 | 2024 | 102 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2860 | 0.050 |
Why?
|
| Cholesterol | 4 | 2016 | 370 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2012 | 1791 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2014 | 63 | 0.050 |
Why?
|
| Cannabis | 1 | 1984 | 40 | 0.050 |
Why?
|
| Cell Separation | 3 | 1994 | 205 | 0.050 |
Why?
|
| Photochemistry | 2 | 2002 | 38 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 65 | 0.050 |
Why?
|
| Drug Discovery | 2 | 2018 | 118 | 0.050 |
Why?
|
| Lactation | 1 | 2023 | 55 | 0.050 |
Why?
|
| Income | 1 | 2023 | 90 | 0.050 |
Why?
|
| Bone Marrow Examination | 1 | 2003 | 46 | 0.050 |
Why?
|
| Urate Oxidase | 1 | 2003 | 11 | 0.050 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2007 | 109 | 0.050 |
Why?
|
| Genes | 3 | 1990 | 308 | 0.050 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 2 | 2012 | 20 | 0.050 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 1763 | 0.050 |
Why?
|
| Palliative Care | 2 | 2019 | 273 | 0.050 |
Why?
|
| Hyperuricemia | 1 | 2003 | 25 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2002 | 31 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 567 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 108 | 0.050 |
Why?
|
| Biomarkers | 2 | 2015 | 1933 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 51 | 0.050 |
Why?
|
| Cytokines | 2 | 2018 | 872 | 0.050 |
Why?
|
| Feeding and Eating Disorders | 1 | 1985 | 186 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2883 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2023 | 135 | 0.050 |
Why?
|
| Colony-Stimulating Factors | 3 | 1987 | 14 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2004 | 139 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 111 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 108 | 0.050 |
Why?
|
| Protein Binding | 2 | 2018 | 1561 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2004 | 467 | 0.050 |
Why?
|
| Cell Division | 5 | 1992 | 705 | 0.050 |
Why?
|
| Prednisone | 5 | 1996 | 258 | 0.050 |
Why?
|
| Plasmids | 2 | 1993 | 291 | 0.050 |
Why?
|
| Affect | 1 | 1985 | 397 | 0.050 |
Why?
|
| Cetrimonium Compounds | 1 | 2002 | 2 | 0.050 |
Why?
|
| Deoxyribonuclease I | 1 | 2002 | 30 | 0.050 |
Why?
|
| Borohydrides | 1 | 2002 | 7 | 0.050 |
Why?
|
| Fever | 2 | 1996 | 131 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 122 | 0.050 |
Why?
|
| Aldehyde Reductase | 1 | 2021 | 10 | 0.050 |
Why?
|
| Myeloablative Agonists | 2 | 2014 | 38 | 0.050 |
Why?
|
| Family | 3 | 2012 | 332 | 0.050 |
Why?
|
| Preleukemia | 3 | 1986 | 11 | 0.050 |
Why?
|
| Voluntary Health Agencies | 1 | 2021 | 5 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 3147 | 0.050 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 72 | 0.040 |
Why?
|
| Skin Diseases, Infectious | 1 | 2001 | 12 | 0.040 |
Why?
|
| Stem Cells | 1 | 1984 | 394 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2023 | 255 | 0.040 |
Why?
|
| Toxicology | 1 | 2021 | 18 | 0.040 |
Why?
|
| Echocardiography | 1 | 2007 | 1004 | 0.040 |
Why?
|
| Tacrolimus | 2 | 2015 | 373 | 0.040 |
Why?
|
| International Agencies | 2 | 2012 | 34 | 0.040 |
Why?
|
| Immunoblastic Lymphadenopathy | 2 | 1996 | 6 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2008 | 910 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 1984 | 287 | 0.040 |
Why?
|
| Cell Line | 4 | 2016 | 2533 | 0.040 |
Why?
|
| Creatinine | 1 | 2002 | 299 | 0.040 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2001 | 4 | 0.040 |
Why?
|
| Silicates | 1 | 2001 | 10 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 27 | 0.040 |
Why?
|
| Television | 1 | 2001 | 29 | 0.040 |
Why?
|
| Mood Disorders | 1 | 2001 | 83 | 0.040 |
Why?
|
| Transcription, Genetic | 6 | 2006 | 1192 | 0.040 |
Why?
|
| New Mexico | 1 | 2020 | 3 | 0.040 |
Why?
|
| Length of Stay | 2 | 2008 | 833 | 0.040 |
Why?
|
| Survival | 1 | 2000 | 21 | 0.040 |
Why?
|
| Rosette Formation | 3 | 1984 | 33 | 0.040 |
Why?
|
| Expressed Sequence Tags | 3 | 2006 | 35 | 0.040 |
Why?
|
| Hydrazines | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1761 | 0.040 |
Why?
|
| Sepsis | 1 | 1984 | 391 | 0.040 |
Why?
|
| Laboratories | 1 | 2020 | 48 | 0.040 |
Why?
|
| Illinois | 2 | 2012 | 531 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2020 | 50 | 0.040 |
Why?
|
| Megakaryocytes | 2 | 1998 | 39 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2000 | 29 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 2059 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2000 | 71 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2020 | 91 | 0.040 |
Why?
|
| Patient Selection | 2 | 2019 | 709 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2012 | 110 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 110 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 157 | 0.040 |
Why?
|
| RNA | 3 | 2016 | 606 | 0.040 |
Why?
|
| Focal Infection, Dental | 1 | 1999 | 3 | 0.040 |
Why?
|
| Dental Care for Chronically Ill | 1 | 1999 | 4 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2018 | 2614 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 212 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 568 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 299 | 0.040 |
Why?
|
| Historically Controlled Study | 1 | 2019 | 6 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 70 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 311 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 770 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2001 | 183 | 0.040 |
Why?
|
| Heart Failure | 4 | 2009 | 1422 | 0.040 |
Why?
|
| Stereoisomerism | 3 | 2008 | 104 | 0.040 |
Why?
|
| Proteins | 2 | 2003 | 816 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3490 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2012 | 392 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2018 | 7 | 0.040 |
Why?
|
| GATA1 Transcription Factor | 1 | 2018 | 19 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 98 | 0.040 |
Why?
|
| Histiocytes | 1 | 1998 | 25 | 0.030 |
Why?
|
| Mental Health | 1 | 2019 | 202 | 0.030 |
Why?
|
| Lovastatin | 2 | 1991 | 29 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2018 | 82 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 101 | 0.030 |
Why?
|
| Harringtonines | 2 | 2008 | 4 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2017 | 4 | 0.030 |
Why?
|
| Pedigree | 2 | 2016 | 982 | 0.030 |
Why?
|
| Sulfuric Acids | 1 | 1997 | 6 | 0.030 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 1997 | 2 | 0.030 |
Why?
|
| Genes, myc | 2 | 1994 | 41 | 0.030 |
Why?
|
| Anemia, Aplastic | 2 | 2012 | 35 | 0.030 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1997 | 11 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 2 | 2004 | 85 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2016 | 18 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 192 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Styrenes | 1 | 1996 | 7 | 0.030 |
Why?
|
| Benzene | 1 | 1996 | 8 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2015 | 815 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 172 | 0.030 |
Why?
|
| Interferon Type I | 2 | 2006 | 206 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1997 | 213 | 0.030 |
Why?
|
| Chromosomes, Human, 6-12 and X | 3 | 1986 | 23 | 0.030 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 69 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 18 | 0.030 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2016 | 14 | 0.030 |
Why?
|
| Mitomycin | 3 | 2003 | 29 | 0.030 |
Why?
|
| Chromosomes, Human, 4-5 | 2 | 1986 | 10 | 0.030 |
Why?
|
| Models, Econometric | 1 | 2016 | 15 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2007 | 2591 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 3240 | 0.030 |
Why?
|
| Digestive System Diseases | 1 | 1996 | 19 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.030 |
Why?
|
| Somatoform Disorders | 1 | 1996 | 31 | 0.030 |
Why?
|
| Personality Assessment | 1 | 1996 | 99 | 0.030 |
Why?
|
| Markov Chains | 1 | 2016 | 137 | 0.030 |
Why?
|
| Morbidity | 1 | 1996 | 160 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 1998 | 50 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2000 | 463 | 0.030 |
Why?
|
| Aziridines | 2 | 2005 | 9 | 0.030 |
Why?
|
| Exome | 1 | 2016 | 141 | 0.030 |
Why?
|
| Thioguanine | 1 | 1995 | 17 | 0.030 |
Why?
|
| Benzoquinones | 2 | 2005 | 27 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 157 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 1995 | 41 | 0.030 |
Why?
|
| Pharmacogenomic Testing | 1 | 2016 | 107 | 0.030 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 1992 | 30 | 0.030 |
Why?
|
| Ticlopidine | 1 | 1995 | 26 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1994 | 3 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 154 | 0.030 |
Why?
|
| Leukopenia | 1 | 1995 | 68 | 0.030 |
Why?
|
| Chromatin | 1 | 2018 | 446 | 0.030 |
Why?
|
| Genes, fms | 1 | 1994 | 2 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 79 | 0.030 |
Why?
|
| Coma | 1 | 1995 | 52 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1157 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 922 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 1994 | 22 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2005 | 67 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 157 | 0.030 |
Why?
|
| Psychometrics | 1 | 1996 | 340 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 53 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1175 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 631 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 197 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2001 | 727 | 0.030 |
Why?
|
| Warfarin | 1 | 1995 | 107 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 33 | 0.030 |
Why?
|
| B-Lymphocytes | 5 | 1999 | 771 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 165 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 880 | 0.030 |
Why?
|
| Mitogens | 2 | 1984 | 61 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 120 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2014 | 28 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 706 | 0.030 |
Why?
|
| Monosomy | 2 | 1995 | 12 | 0.030 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2013 | 7 | 0.030 |
Why?
|
| Emergency Medical Technicians | 1 | 1993 | 14 | 0.030 |
Why?
|
| Thoracostomy | 1 | 1993 | 10 | 0.030 |
Why?
|
| Liposarcoma | 1 | 1993 | 11 | 0.030 |
Why?
|
| Intubation | 1 | 1993 | 23 | 0.030 |
Why?
|
| Gene Amplification | 2 | 2007 | 143 | 0.030 |
Why?
|
| Gene Library | 2 | 2006 | 134 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1993 | 37 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 1874 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 1991 | 2943 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 501 | 0.020 |
Why?
|
| Lung | 1 | 2000 | 1382 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 315 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 102 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 312 | 0.020 |
Why?
|
| Antigens, Differentiation | 2 | 1990 | 141 | 0.020 |
Why?
|
| Dogs | 1 | 2014 | 719 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 39 | 0.020 |
Why?
|
| Drug Evaluation | 2 | 2008 | 136 | 0.020 |
Why?
|
| Monoterpenes | 1 | 1992 | 6 | 0.020 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1993 | 186 | 0.020 |
Why?
|
| Terpenes | 1 | 1992 | 18 | 0.020 |
Why?
|
| Thalidomide | 1 | 2012 | 56 | 0.020 |
Why?
|
| Cloning, Molecular | 3 | 2002 | 648 | 0.020 |
Why?
|
| Free Radicals | 1 | 1992 | 71 | 0.020 |
Why?
|
| Aspergillosis | 1 | 1992 | 39 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1992 | 60 | 0.020 |
Why?
|
| F-Box Proteins | 1 | 2012 | 14 | 0.020 |
Why?
|
| Biopsy | 2 | 1993 | 1220 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 102 | 0.020 |
Why?
|
| Chromosomes, Human, 21-22 and Y | 2 | 1982 | 14 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 64 | 0.020 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2002 | 8 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 308 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 66 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2016 | 873 | 0.020 |
Why?
|
| Singapore | 1 | 2011 | 15 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 32 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1991 | 71 | 0.020 |
Why?
|
| Depression | 1 | 1996 | 560 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 82 | 0.020 |
Why?
|
| Anticoagulants | 1 | 1995 | 463 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 124 | 0.020 |
Why?
|
| London | 1 | 2011 | 17 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 164 | 0.020 |
Why?
|
| Data Collection | 1 | 2012 | 381 | 0.020 |
Why?
|
| Complement C1q | 1 | 1991 | 13 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1990 | 17 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 301 | 0.020 |
Why?
|
| Heterozygote | 1 | 1992 | 382 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 1990 | 12 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2014 | 357 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 59 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 855 | 0.020 |
Why?
|
| Blotting, Northern | 3 | 1998 | 258 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2004 | 307 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1991 | 218 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 289 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2010 | 45 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2163 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 179 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2004 | 798 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 214 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 444 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 257 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1158 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 454 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 2010 | 46 | 0.020 |
Why?
|
| Semantic Differential | 1 | 1989 | 1 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 70 | 0.020 |
Why?
|
| Interferons | 1 | 2010 | 130 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2010 | 148 | 0.020 |
Why?
|
| Psychology, Child | 1 | 1989 | 12 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 1991 | 182 | 0.020 |
Why?
|
| Muscle Cramp | 1 | 2009 | 5 | 0.020 |
Why?
|
| Zinc Fingers | 2 | 2003 | 60 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 2012 | 276 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 136 | 0.020 |
Why?
|
| Hydrochloric Acid | 1 | 2009 | 11 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 1989 | 35 | 0.020 |
Why?
|
| Sister Chromatid Exchange | 1 | 1989 | 13 | 0.020 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 2 | 0.020 |
Why?
|
| Edema | 1 | 2009 | 73 | 0.020 |
Why?
|
| Mitomycins | 2 | 1989 | 13 | 0.020 |
Why?
|
| Liposomes | 1 | 2009 | 101 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 4 | 1990 | 118 | 0.020 |
Why?
|
| Injections | 1 | 2009 | 126 | 0.020 |
Why?
|
| Singlet Oxygen | 1 | 1988 | 7 | 0.020 |
Why?
|
| Photolysis | 1 | 1988 | 13 | 0.020 |
Why?
|
| Face | 1 | 1989 | 115 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 223 | 0.020 |
Why?
|
| Clone Cells | 2 | 2003 | 223 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 367 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2009 | 68 | 0.020 |
Why?
|
| Nitrosourea Compounds | 1 | 1988 | 9 | 0.020 |
Why?
|
| RNA Probes | 1 | 2008 | 16 | 0.020 |
Why?
|
| Interleukins | 1 | 1989 | 134 | 0.020 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 99 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
| Dermatomycoses | 1 | 1988 | 11 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 1988 | 232 | 0.020 |
Why?
|
| Peritonitis | 1 | 1988 | 29 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1103 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 86 | 0.020 |
Why?
|
| Isoleucine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2007 | 67 | 0.020 |
Why?
|
| Electrochemistry | 1 | 1987 | 60 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 467 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 517 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 246 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1993 | 854 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1987 | 14 | 0.020 |
Why?
|
| Glucose | 1 | 2010 | 701 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2007 | 20 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 147 | 0.020 |
Why?
|
| Hematology | 1 | 2007 | 31 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1991 | 395 | 0.020 |
Why?
|
| In Vitro Techniques | 3 | 1994 | 1010 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1987 | 137 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 126 | 0.020 |
Why?
|
| Aspartate Carbamoyltransferase | 1 | 1986 | 1 | 0.020 |
Why?
|
| Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) | 1 | 1986 | 1 | 0.020 |
Why?
|
| Dihydroorotase | 1 | 1986 | 1 | 0.020 |
Why?
|
| Avian Myeloblastosis Virus | 1 | 1986 | 1 | 0.020 |
Why?
|
| Avian Leukosis Virus | 1 | 1986 | 4 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 249 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 1986 | 63 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.020 |
Why?
|
| Temperature | 1 | 1987 | 426 | 0.020 |
Why?
|
| Teniposide | 1 | 1985 | 6 | 0.010 |
Why?
|
| PubMed | 1 | 2005 | 16 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1986 | 65 | 0.010 |
Why?
|
| Tongue Diseases | 1 | 1985 | 9 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 2005 | 27 | 0.010 |
Why?
|
| Cisplatin | 1 | 1987 | 611 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 3 | 1992 | 242 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 395 | 0.010 |
Why?
|
| Aerosols | 2 | 1997 | 48 | 0.010 |
Why?
|
| Work | 1 | 1985 | 15 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1988 | 385 | 0.010 |
Why?
|
| Southwestern United States | 1 | 2004 | 7 | 0.010 |
Why?
|
| Genes, Dominant | 2 | 1996 | 116 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1984 | 113 | 0.010 |
Why?
|
| Catalase | 1 | 1984 | 49 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1984 | 63 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 2781 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 2004 | 24 | 0.010 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.010 |
Why?
|
| Periodontal Diseases | 2 | 1999 | 10 | 0.010 |
Why?
|
| Tooth Extraction | 2 | 1999 | 12 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2005 | 161 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1986 | 623 | 0.010 |
Why?
|
| Metalloproteins | 1 | 2004 | 17 | 0.010 |
Why?
|
| Osteolysis | 1 | 1984 | 15 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 365 | 0.010 |
Why?
|
| LIM Domain Proteins | 1 | 2004 | 25 | 0.010 |
Why?
|
| Cattle | 1 | 1984 | 387 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1984 | 45 | 0.010 |
Why?
|
| Cytochalasins | 1 | 1983 | 3 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1983 | 42 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1984 | 62 | 0.010 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1983 | 41 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1984 | 151 | 0.010 |
Why?
|
| Oxygen | 1 | 1988 | 788 | 0.010 |
Why?
|
| Social Environment | 1 | 1985 | 195 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1993 | 41 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group G Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
| Procarbazine | 3 | 1990 | 38 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2003 | 4 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2003 | 3 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 2003 | 30 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2003 | 9 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 1984 | 154 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2003 | 24 | 0.010 |
Why?
|
| Naphthalenes | 1 | 1983 | 41 | 0.010 |
Why?
|
| S Phase | 2 | 1993 | 64 | 0.010 |
Why?
|
| Bleomycin | 3 | 1990 | 103 | 0.010 |
Why?
|
| Allopurinol | 1 | 2003 | 78 | 0.010 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2002 | 20 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 220 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2002 | 35 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2002 | 15 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 584 | 0.010 |
Why?
|
| Anemia, Refractory | 2 | 1996 | 5 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1985 | 338 | 0.010 |
Why?
|
| Laparotomy | 1 | 1982 | 69 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 119 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 145 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1982 | 138 | 0.010 |
Why?
|
| Lymph Nodes | 2 | 1982 | 565 | 0.010 |
Why?
|
| Ontario | 1 | 2001 | 56 | 0.010 |
Why?
|
| CD13 Antigens | 1 | 2001 | 5 | 0.010 |
Why?
|
| CD56 Antigen | 1 | 2001 | 18 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 2001 | 22 | 0.010 |
Why?
|
| Interleukin-5 | 2 | 1993 | 36 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2001 | 23 | 0.010 |
Why?
|
| Aluminum Silicates | 1 | 2001 | 2 | 0.010 |
Why?
|
| Multigene Family | 1 | 2002 | 213 | 0.010 |
Why?
|
| Chromosomes, Artificial, Human | 1 | 2001 | 2 | 0.010 |
Why?
|
| Apc8 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 2 | 0.010 |
Why?
|
| Soil Pollutants | 1 | 2001 | 8 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2001 | 78 | 0.010 |
Why?
|
| Spleen | 1 | 1982 | 439 | 0.010 |
Why?
|
| Mitosis | 1 | 1981 | 159 | 0.010 |
Why?
|
| Interleukin-4 | 2 | 1993 | 136 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2002 | 294 | 0.010 |
Why?
|
| Chromosomes, Bacterial | 1 | 2000 | 30 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2000 | 32 | 0.010 |
Why?
|
| Amifostine | 1 | 2000 | 51 | 0.010 |
Why?
|
| Ki-1 Antigen | 2 | 1990 | 19 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 99 | 0.010 |
Why?
|
| Cell Transformation, Viral | 2 | 1990 | 39 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1981 | 229 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2001 | 411 | 0.010 |
Why?
|
| Gingivitis | 1 | 1999 | 1 | 0.010 |
Why?
|
| Dental Caries | 1 | 1999 | 4 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 214 | 0.010 |
Why?
|
| Case Management | 1 | 1999 | 29 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1167 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 2 | 1990 | 126 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2000 | 599 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 28 | 0.010 |
Why?
|
| Reference Values | 2 | 1990 | 675 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 510 | 0.010 |
Why?
|
| Algorithms | 1 | 2006 | 2014 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 983 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 684 | 0.010 |
Why?
|
| Air Pollutants, Occupational | 1 | 1997 | 6 | 0.010 |
Why?
|
| Styrene | 1 | 1996 | 1 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2040 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1998 | 482 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 1997 | 89 | 0.010 |
Why?
|
| Leucovorin | 2 | 1990 | 227 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1996 | 8 | 0.010 |
Why?
|
| Anemia, Sideroblastic | 1 | 1996 | 7 | 0.010 |
Why?
|
| Erythropoiesis | 1 | 1996 | 53 | 0.010 |
Why?
|
| Vinblastine | 2 | 1988 | 100 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1996 | 89 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 304 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1995 | 19 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1987 | 2463 | 0.010 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 1994 | 1 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1994 | 21 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1994 | 47 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 18 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1994 | 71 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1994 | 41 | 0.010 |
Why?
|
| Hematocrit | 1 | 1994 | 69 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 152 | 0.010 |
Why?
|
| Interleukin-9 | 1 | 1993 | 3 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1994 | 72 | 0.010 |
Why?
|
| Cell Count | 1 | 1994 | 203 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 1993 | 39 | 0.010 |
Why?
|
| Transcription Factor CHOP | 1 | 1993 | 16 | 0.010 |
Why?
|
| Arabinofuranosylcytosine Triphosphate | 1 | 1993 | 1 | 0.010 |
Why?
|
| Chest Tubes | 1 | 1993 | 21 | 0.010 |
Why?
|
| RNA-Binding Protein FUS | 1 | 1993 | 9 | 0.010 |
Why?
|
| Medical Audit | 1 | 1993 | 41 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1993 | 41 | 0.010 |
Why?
|
| Blood Cells | 1 | 1993 | 34 | 0.010 |
Why?
|
| Aircraft | 1 | 1993 | 26 | 0.010 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1993 | 21 | 0.010 |
Why?
|
| Acetates | 2 | 1983 | 69 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 134 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1992 | 58 | 0.010 |
Why?
|
| Copper | 1 | 1993 | 81 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 1992 | 10 | 0.010 |
Why?
|
| Trauma Centers | 1 | 1993 | 174 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 147 | 0.010 |
Why?
|
| Fungi | 1 | 1992 | 67 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1993 | 351 | 0.010 |
Why?
|
| Interphase | 1 | 1991 | 37 | 0.010 |
Why?
|
| X Chromosome | 1 | 1991 | 157 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1992 | 262 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 463 | 0.000 |
Why?
|
| Genes, Immunoglobulin | 1 | 1990 | 111 | 0.000 |
Why?
|
| Lymphoma, Follicular | 1 | 1990 | 74 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 2092 | 0.000 |
Why?
|
| Homozygote | 1 | 1990 | 208 | 0.000 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1989 | 16 | 0.000 |
Why?
|
| Centromere | 1 | 1988 | 27 | 0.000 |
Why?
|
| Mechlorethamine | 1 | 1988 | 11 | 0.000 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 1988 | 9 | 0.000 |
Why?
|
| Metaphase | 1 | 1987 | 25 | 0.000 |
Why?
|
| Dacarbazine | 1 | 1988 | 101 | 0.000 |
Why?
|
| Rectal Neoplasms | 1 | 1988 | 134 | 0.000 |
Why?
|
| Fingers | 1 | 1987 | 70 | 0.000 |
Why?
|
| Personality | 1 | 1988 | 140 | 0.000 |
Why?
|
| Attitude to Health | 1 | 1988 | 226 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1986 | 97 | 0.000 |
Why?
|
| Chromosomes, Human, 19-20 | 1 | 1986 | 5 | 0.000 |
Why?
|
| Leukocytes | 1 | 1987 | 218 | 0.000 |
Why?
|
| Dental Pulp Diseases | 1 | 1986 | 2 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1986 | 333 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1986 | 71 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1987 | 236 | 0.000 |
Why?
|
| Mitosporic Fungi | 1 | 1985 | 3 | 0.000 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1986 | 107 | 0.000 |
Why?
|
| Ischemia | 1 | 1987 | 257 | 0.000 |
Why?
|
| Radiation Injuries | 1 | 1986 | 163 | 0.000 |
Why?
|
| Syndrome | 1 | 1985 | 453 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1984 | 132 | 0.000 |
Why?
|
| Retroviridae Infections | 1 | 1984 | 46 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1988 | 432 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1984 | 173 | 0.000 |
Why?
|
| Optical Rotation | 1 | 1983 | 2 | 0.000 |
Why?
|
| Hydroxycholesterols | 1 | 1983 | 7 | 0.000 |
Why?
|
| Monocytes | 1 | 1983 | 231 | 0.000 |
Why?
|